Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Hellenic Cooperative Oncology Group40 enrolled

Overview

The present study will evaluate the use of osimertinib as 1st line therapy for patients with advanced EGFR positive non-small cell lung cancer who are treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.

This will be an observational, multicentric, retrospective/ prospective analysis of patients with advanced EGFR positive non-small cell lung cancer that receive osimertinib as 1st line therapy. The patient data will be collected at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology during scheduled patient clinical visits, from February 2020 for a total period of three years. The biological material obtained from the patients of this analysis will be possibly used in a future translational study as an exploratory analysis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lung Cancer Non-small Cell Stage IV

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * men or women of 18 years or older that live in Greece * histologically or cytologically confirmed, advanced EGFR positive non-small cell lung cancer * untreated patients for advanced NSCLC * patients who are expected to receive osimertinib regardless of their enrollment in the study * signed written informed consent Exclusion Criteria: * patients with cancer other than NSCLC that require treatment * pretreated patients for NSCLC * patients that receive or are expected to receive or have received an investigational drug/product/intervention

Locations (1)

Hellenic Cooperative Oncology Group

Athens, Greece

RECRUITING

Outcomes

Primary Outcomes

progression-free survival (PFS)

the time from treatment initiation to either the first documented disease progression or death from any cause